Vincent P Groot1,2, Georgios Gemenetzis1, Alex B Blair1, Ding Ding1, Ammar A Javed1, Richard A Burkhart1, Jun Yu1, Inne H Borel Rinkes2, I Quintus Molenaar2, John L Cameron1, Elliot K Fishman3, Ralph H Hruban4, Matthew J Weiss1, Christopher L Wolfgang1, Jin He5. 1. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. 2. Department of Surgery, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Radiology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. jhe11@jhmi.edu.
Abstract
BACKGROUND: After radical resection of pancreatic ductal adenocarcinoma (PDAC), approximately 80% of patients will develop disease recurrence. It remains unclear to what extent the location of recurrence carries prognostic significance. Additionally, stratifying the pattern of recurrence may lead to a deeper understanding of the heterogeneous biological behavior of PDAC. OBJECTIVE: The aim of this study was to characterize the relationship of recurrence patterns with survival in patients with resected PDAC. METHODS: This single-center cohort study included patients undergoing pancreatectomy at the Johns Hopkins Hospital between 2000 and 2013. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. Sites of first recurrence were stratified into five groups and survival outcomes were estimated using Kaplan-Meier curves. The association of specific recurrence locations with overall survival (OS) was analyzed using Cox proportional-hazards models with and without landmark analysis. RESULTS: Accurate follow-up data were available for 877 patients, 662 (75.5%) of whom had documented recurrence at last follow-up. Patients with multiple-site (n = 227, 4.7 months) or liver-only recurrence (n = 166, 7.2 months) had significantly worse median survival after recurrence when compared with lung- (n = 93) or local-only (n = 158) recurrence (15.4 and 9.7 months, respectively). On multivariable analysis, the unique recurrence patterns had variable predictive values for OS. Landmark analyses, with landmarks set at 12, 18, and 24 months, confirmed these findings. CONCLUSIONS: This study demonstrates that specific patterns of PDAC recurrence result in different survival outcomes. Furthermore, distinct first recurrence locations have unique independent predictive values for OS, which could help with prognostic stratification and decisions regarding treatment after the diagnosis of recurrence.
BACKGROUND: After radical resection of pancreatic ductal adenocarcinoma (PDAC), approximately 80% of patients will develop disease recurrence. It remains unclear to what extent the location of recurrence carries prognostic significance. Additionally, stratifying the pattern of recurrence may lead to a deeper understanding of the heterogeneous biological behavior of PDAC. OBJECTIVE: The aim of this study was to characterize the relationship of recurrence patterns with survival in patients with resected PDAC. METHODS: This single-center cohort study included patients undergoing pancreatectomy at the Johns Hopkins Hospital between 2000 and 2013. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. Sites of first recurrence were stratified into five groups and survival outcomes were estimated using Kaplan-Meier curves. The association of specific recurrence locations with overall survival (OS) was analyzed using Cox proportional-hazards models with and without landmark analysis. RESULTS: Accurate follow-up data were available for 877 patients, 662 (75.5%) of whom had documented recurrence at last follow-up. Patients with multiple-site (n = 227, 4.7 months) or liver-only recurrence (n = 166, 7.2 months) had significantly worse median survival after recurrence when compared with lung- (n = 93) or local-only (n = 158) recurrence (15.4 and 9.7 months, respectively). On multivariable analysis, the unique recurrence patterns had variable predictive values for OS. Landmark analyses, with landmarks set at 12, 18, and 24 months, confirmed these findings. CONCLUSIONS: This study demonstrates that specific patterns of PDAC recurrence result in different survival outcomes. Furthermore, distinct first recurrence locations have unique independent predictive values for OS, which could help with prognostic stratification and decisions regarding treatment after the diagnosis of recurrence.
Authors: Jonathan M Hernandez; Connor A Morton; Sam Al-Saadi; Desireé Villadolid; Jennifer Cooper; Carl Bowers; Alexander S Rosemurgy Journal: Am Surg Date: 2010-05 Impact factor: 0.688
Authors: George J Arnaoutakis; Deepa Rangachari; Daniel A Laheru; Chris A Iacobuzio-Donahue; Ralph H Hruban; Joseph M Herman; Barish H Edil; Timothy M Pawlik; Richard D Schulick; John L Cameron; Avedis Meneshian; Stephen C Yang; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2011-07-02 Impact factor: 3.452
Authors: Vincent P Groot; Lois A Daamen; Jeroen Hagendoorn; Inne H M Borel Rinkes; Hjalmar C van Santvoort; I Quintus Molenaar Journal: J Surg Res Date: 2017-09-21 Impact factor: 2.192
Authors: Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He Journal: Ann Surg Date: 2018-05 Impact factor: 12.969
Authors: Katherine E Poruk; Yuhree Kim; John L Cameron; Jin He; Frederic E Eckhauser; Neda Rezaee; Joseph Herman; Daniel Laheru; Lei Zheng; Elliot K Fishman; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: J Gastrointest Surg Date: 2015-01-17 Impact factor: 3.452
Authors: Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: Ann Surg Date: 2019-06 Impact factor: 13.787
Authors: Vincent P Groot; Stacy Mosier; Ammar A Javed; Jonathan A Teinor; Georgios Gemenetzis; Ding Ding; Lisa M Haley; Jun Yu; Richard A Burkhart; Alina Hasanain; Marija Debeljak; Hirohiko Kamiyama; Amol Narang; Daniel A Laheru; Lei Zheng; Ming-Tseh Lin; Christopher D Gocke; Elliot K Fishman; Ralph H Hruban; Michael G Goggins; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Victor E Velculescu; Jin He; Christopher L Wolfgang; James R Eshleman Journal: Clin Cancer Res Date: 2019-05-29 Impact factor: 13.801
Authors: Toni T Seppälä; Jacquelyn W Zimmerman; Elisabetta Sereni; Dennis Plenker; Reecha Suri; Noah Rozich; Alex Blair; Dwayne L Thomas; Jonathan Teinor; Ammar Javed; Hardik Patel; John L Cameron; William R Burns; Jin He; David A Tuveson; Elizabeth M Jaffee; James Eshleman; Annamaria Szabolcs; David P Ryan; David T Ting; Christopher L Wolfgang; Richard A Burkhart Journal: Ann Surg Date: 2020-09-01 Impact factor: 13.787